# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-24-104372
Filing Date
2024-09-30
Accepted
2024-09-30 17:13:32
Documents
7
Period of Report
2024-10-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm2425198d1_def14a.htm | DEF 14A | 490948
2 | GRAPHIC | tm2424296d1_pre14asp01img01.jpg | GRAPHIC | 2945
3 | GRAPHIC | tm2424296d1_pre14aimg001.jpg | GRAPHIC | 147510
4 | GRAPHIC | tm2424296d1_pre14aimg002.jpg | GRAPHIC | 140076
5 | GRAPHIC | tm2424296d1_pre14asp01img02.jpg | GRAPHIC | 473266
6 | GRAPHIC | proxy1.jpg | GRAPHIC | 311016
7 | GRAPHIC | proxy2.jpg | GRAPHIC | 204956
| Complete submission text file | 0001104659-24-104372.txt |  | 2255195

Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-12584 | Film No.: 241340372
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)